1. Biopharmaceuticals against substance use disorders – Present and future
   Theofanis Vavilis et al, 2023, European Journal of Pharmacology CrossRef
2. Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer
   Joshua Tobias et al, 2022, Cancers CrossRef
3. Immunogenicity of biologics used in the treatment of asthma
   Omario A.M. Neunie et al, 2024, Human Antibodies CrossRef
4. Rational design of antibody‐like peptides for targeting the human complement fragment protein C5a
   Manaswini Ghosh et al, 2024, Proteins: Structure, Function, and Bioinformatics CrossRef
5. Therapeutic Applications of Aptamers
   George Santarpia et al, 2024, International Journal of Molecular Sciences CrossRef
6. Biological products in medicine
   Marzieh Daniali et al, 2024, Encyclopedia of Toxicology CrossRef
7. Immune Reactions in Major Types of Oncological Treatment
   Patrycja Kozubek et al, 2023, International Journal of Molecular Sciences CrossRef
8. HLAII peptide presentation of infliximab increases when complexed with TNF
   Andrea Casasola-LaMacchia et al, 2022, Frontiers in Immunology CrossRef
9. EVALUATION OF DRUG SIDE EFFECT PROFILES IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE USING TUMOR NECROSIS FACTOR-ALPHA INHIBITORS
   Ceren Demir et al, 2024, Rheumatology Quarterly CrossRef
10. Hypersensitivity Reactions to Monoclonal Antibodies: New Approaches
    Sonia Gelis et al, 2022, Current Treatment Options in Allergy CrossRef
11. Vaccination against Her-2/neu, with focus on peptide-based vaccines
    J. Tobias et al, 2022, ESMO Open CrossRef
12. Managing Severe Adverse Reactions to Biologicals in Severe Asthma
    Radu-Gheorghe Balan et al, 2023, Biomedicines CrossRef
13. Current and future use of antibody-based passive immunity to prevent or control HBV/HDV infections
    Adam J. Gehring et al, 2024, Antiviral Research CrossRef